› Forums › General Melanoma Community › interesting phase I trial
- This topic has 3 replies, 1 voice, and was last updated 10 years, 11 months ago by
ed williams.
- Post
-
- March 21, 2015 at 12:41 am
A VGEF drug (Ziv-alfibercept) in combo with pembro.
Unfortunately It looks like any prior immunotherapy treatment is a disqualfier
- Replies
-
-
- March 21, 2015 at 1:32 pm
Thanks Brian for the link. This is the future, combination with Pd-1 drugs to see what works best. There is a video on youtube with Dr. Omid Hamid of " The Angeles Clinic" , where he talks about this combination targeted therapy and others. The title of the video is " Future therapies for Melanoma" from the 2014 symposium at the Angeles Clinic. Dr. Omid explains the science in the video, he also goes into several other pathways other than Pd-1 that will be targeted in the future. Wishing all the warriors the best!!! Ed
-
- March 21, 2015 at 1:32 pm
Thanks Brian for the link. This is the future, combination with Pd-1 drugs to see what works best. There is a video on youtube with Dr. Omid Hamid of " The Angeles Clinic" , where he talks about this combination targeted therapy and others. The title of the video is " Future therapies for Melanoma" from the 2014 symposium at the Angeles Clinic. Dr. Omid explains the science in the video, he also goes into several other pathways other than Pd-1 that will be targeted in the future. Wishing all the warriors the best!!! Ed
-
- March 21, 2015 at 1:32 pm
Thanks Brian for the link. This is the future, combination with Pd-1 drugs to see what works best. There is a video on youtube with Dr. Omid Hamid of " The Angeles Clinic" , where he talks about this combination targeted therapy and others. The title of the video is " Future therapies for Melanoma" from the 2014 symposium at the Angeles Clinic. Dr. Omid explains the science in the video, he also goes into several other pathways other than Pd-1 that will be targeted in the future. Wishing all the warriors the best!!! Ed
-
- You must be logged in to reply to this topic.